Terms: = Prostate cancer AND NACA, HSD48, 4666, ENSG00000196531, MGC117224, NACA1, Q13765, FKSG17, NACAP1
3 results:
1. A genome-wide pleiotropy scan for prostate cancer risk.
Panagiotou OA; Travis RC; Campa D; Berndt SI; Lindstrom S; Kraft P; Schumacher FR; Siddiq A; Papatheodorou SI; Stanford JL; Albanes D; Virtamo J; Weinstein SJ; Diver WR; Gapstur SM; Stevens VL; Boeing H; Bueno-de-Mesquita HB; Barricarte Gurrea A; Kaaks R; Khaw KT; Krogh V; Overvad K; Riboli E; Trichopoulos D; Giovannucci E; Stampfer M; Haiman C; Henderson B; Le Marchand L; Gaziano JM; Hunter DJ; Koutros S; Yeager M; Hoover RN; ; Chanock SJ; Wacholder S; Key TJ; Tsilidis KK
Eur Urol; 2015 Apr; 67(4):649-57. PubMed ID: 25277271
[TBL] [Abstract] [Full Text] [Related]
2. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy.
Mydlo JH; Viterbo R; Crispen P
BJU Int; 2005 Apr; 95(6):843-6. PubMed ID: 15794795
[TBL] [Abstract] [Full Text] [Related]
3. Immunohistochemical analysis of in vivo patterns of Bcl-X expression.
Krajewski S; Krajewska M; Shabaik A; Wang HG; Irie S; Fong L; Reed JC
Cancer Res; 1994 Nov; 54(21):5501-7. PubMed ID: 7923184
[TBL] [Abstract] [Full Text] [Related]
